Join Growin Stock Community!

Cocrystal pharma, inc.COCP.US Overview

US StockHealthcare
(No presentation for COCP)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

COCP AI Insights

COCP Overall Performance

COCP AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

COCP Recent Performance

1.43%

Cocrystal pharma, inc.

0.05%

Avg of Sector

-0.31%

S&P500

COCP PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

COCP Key Information

COCP Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

COCP Profile

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.

Price of COCP

COCP FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

COCP Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.94
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
92.45
PB Ratio
1.89
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.94
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
92.45
PB Ratio
1.89
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is COCP's latest earnings report released?

    The most recent financial report for Cocrystal pharma, inc. (COCP) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating COCP's short-term business performance and financial health. For the latest updates on COCP's earnings releases, visit this page regularly.

  • How much debt does COCP have?

    As of the end of the reporting period, Cocrystal pharma, inc. (COCP) had total debt of 1.58M, with a debt ratio of 0.15. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does COCP have?

    At the end of the period, Cocrystal pharma, inc. (COCP) held Total Cash and Cash Equivalents of 7.89M, accounting for 0.76 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is COCP's EPS continuing to grow?

    According to the past four quarterly reports, Cocrystal pharma, inc. (COCP)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.19. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of COCP?

    Cocrystal pharma, inc. (COCP)'s Free Cash Flow (FCF) for the period is -1.37M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 73.18% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of COCP?

    The latest valuation data shows Cocrystal pharma, inc. (COCP) has a Price-To-Earnings (PE) ratio of -1.47 and a Price/Earnings-To-Growth (PEG) ratio of 0.34. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.